BTI-322
Based on 1 Customer Validation
BTI-322 is a human IgG1κ antibody directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.15%
- CAS No.: 339181-10-1
- 분자량:146.07 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
CD2
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 Jurkat cells labeling CD2 with BTI-322 (HY-P991543, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 339181-10-1
-
Appearance Liquid
-
분자량 146.07 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Przepiorka, D., et al., (1998). A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood, 92(11), 4066–4071. [Content Brief]
[2]. Xu, Y., et al., (2004). The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletion. Clinical and experimental immunology, 138(3), 476–483. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)